Literature DB >> 8519354

Counselling and testing for HIV infection in Rome 1985-1990: analysis of client characteristics and seroprevalence.

E Girardi1, V Puro, M Colaiacomo, E Lo Presti, D Frigiotti, V Giannini, G Visco, G Ippolito.   

Abstract

To analyze the characteristics of persons seeking HIV testing, and to evaluate the potential effectiveness of a regional program of confidential counselling and testing for HIV infection, we reviewed data on 5127 clients seen from July 1985 to December 1990 in a major counselling and testing site of the city of Rome. During the study period, the number of clients attending the service increased without a parallel rise of the number of newly identified HIV seropositive subjects. Consequently, the seroprevalence rate decreased from 27.6% in the second half of 1985, to 4.3% in the second half of 1990 (p < 0.001). This decrease appears to be associated with the increasing attendance of low risk subjects and of those referred for testing by family practitioner. The study suggests the need for more efficient strategies to reach persons at higher risk for HIV infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8519354     DOI: 10.1007/BF00158786

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  18 in total

1.  HIV-1 counseling and testing sites, Minnesota: analysis of trends in client characteristics.

Authors:  R N Danila; J M Shultz; M T Osterholm; K Henry; M L Simpson; K L MacDonald
Journal:  Am J Public Health       Date:  1990-04       Impact factor: 9.308

2.  The case for wider use of testing for HIV infection.

Authors:  F S Rhame; D G Maki
Journal:  N Engl J Med       Date:  1989-05-11       Impact factor: 91.245

3.  HIV infection as a disease: the medical indications for early diagnosis.

Authors:  P Volberding
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

4.  Seropositivity for HIV at alternate sites.

Authors:  J C Grabau; D L Morse
Journal:  JAMA       Date:  1988-12-02       Impact factor: 56.272

5.  Efficacy of partner notification for HIV infection.

Authors:  J Giesecke; K Ramstedt; F Granath; T Ripa; G Rådö; M Westrell
Journal:  Lancet       Date:  1991-11-02       Impact factor: 79.321

6.  Public Health Service guidelines for counseling and antibody testing to prevent HIV infection and AIDS.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1987-08-14       Impact factor: 17.586

7.  Many people who seek anonymous HIV-antibody testing would avoid it under other circumstances.

Authors:  S M Kegeles; J A Catania; T J Coates; L M Pollack; B Lo
Journal:  AIDS       Date:  1990-06       Impact factor: 4.177

8.  Blind serosurvey of HIV antibodies in newborns in 92 Italian hospitals: a method for monitoring the infection rate in women at time of delivery.

Authors:  G Ippolito; F Costa; M Stegagno; P Angeloni; U Angeloni; E Guzzanti
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

9.  Prevalence of hepatitis B and C viruses and human immunodeficiency virus infections in women of reproductive age.

Authors:  V Puro; E Girardi; G Ippolito; E Lo Presti; A Benedetto; S Zaniratti; V Giannini; C Gioia; S Natili; G Tossini
Journal:  Br J Obstet Gynaecol       Date:  1992-07

Review 10.  Voluntary screening for human immunodeficiency virus (HIV) infection. Weighing the benefits and harms.

Authors:  B Lo; R L Steinbrook; M Cooke; T J Coates; E J Walters; S B Hulley
Journal:  Ann Intern Med       Date:  1989-05-01       Impact factor: 25.391

View more
  2 in total

1.  Demographic and behavioral predictors of knowledge and HIV seropositivity: results of a survey conducted in three anonymous and free counselling and testing centers.

Authors:  I Momas; H Helal; S Prétet; L Marsal; R Poinsard
Journal:  Eur J Epidemiol       Date:  1997-04       Impact factor: 8.082

2.  Temporal trends in reasons for and result of HIV-testing among women in Rome, Italy.

Authors:  V Puro; C D'Ubaldo; M S Aloisi; L Sherr; G Ippolito
Journal:  Eur J Epidemiol       Date:  1998-07       Impact factor: 8.082

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.